These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8556494)

  • 1. Comparison of corticosteroid- and L3T4+ antibody-immunosuppressed mouse models of Pneumocystis carinii pneumonia for evaluation of drugs and leukocytes.
    Bartlett MS; Current WL; Orazi A; Bauer NL; Neiman RS; Queener SF; Smith JW
    Clin Diagn Lab Immunol; 1994 Sep; 1(5):511-6. PubMed ID: 8556494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody to Pneumocystis carinii protects rats and mice from developing pneumonia.
    Bartlett MS; Angus WC; Shaw MM; Durant PJ; Lee CH; Pascale JM; Smith JW
    Clin Diagn Lab Immunol; 1998 Jan; 5(1):74-7. PubMed ID: 9455884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Albendazole inhibits Pneumocystis carinii proliferation in inoculated immunosuppressed mice.
    Bartlett MS; Edlind TD; Lee CH; Dean R; Queener SF; Shaw MM; Smith JW
    Antimicrob Agents Chemother; 1994 Aug; 38(8):1834-7. PubMed ID: 7986016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pneumocystis carinii: improved models to study efficacy of drugs for treatment or prophylaxis of Pneumocystis pneumonia in the rat (Rattus spp.).
    Bartlett MS; Fishman JA; Durkin MM; Queener SF; Smith JW
    Exp Parasitol; 1990 Jan; 70(1):100-6. PubMed ID: 2295322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved rat model of Pneumocystis carinii pneumonia: induced laboratory infections in Pneumocystis-free animals.
    Boylan CJ; Current WL
    Infect Immun; 1992 Apr; 60(4):1589-97. PubMed ID: 1548080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of anti-CD4+ hybridoma cells to induce Pneumocystis carinii in mice.
    McFadden DC; Powles MA; Smith JG; Flattery AM; Bartizal K; Schmatz DM
    Infect Immun; 1994 Nov; 62(11):4887-92. PubMed ID: 7927769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunodeficient and immunosuppressed mice as models to test anti-Pneumocystis carinii drugs.
    Walzer PD; Runck J; Steele P; White M; Linke MJ; Sidman CL
    Antimicrob Agents Chemother; 1997 Feb; 41(2):251-8. PubMed ID: 9021175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammatory responses to Pneumocystis carinii in mice selectively depleted of helper T lymphocytes.
    Beck JM; Warnock ML; Curtis JL; Sniezek MJ; Arraj-Peffer SM; Kaltreider HB; Shellito JE
    Am J Respir Cell Mol Biol; 1991 Aug; 5(2):186-97. PubMed ID: 1679991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pneumocystosis in mice under the conditions of a secondary immunodeficiency and with specific immunological tolerance for Pneumocystis carinii].
    Savitskiĭ IG; Cherniakhovskaia IIu; Kondrat'eva TK; Mikheeva NV
    Zh Mikrobiol Epidemiol Immunobiol; 1994; (1):88-91. PubMed ID: 8184622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production of a monoclonal antibody using lymphocytes from Pneumocystis infected mice.
    Soulez B; Palluault F; Dei-Cas E; Aliouat EM; Camus D
    J Protozool; 1991; 38(6):189S-190S. PubMed ID: 1818162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of organism burden and alveolar macrophage counts during infection with Pneumocystis carinii and recovery.
    Lasbury ME; Durant PJ; Bartlett MS; Smith JW; Lee CH
    Clin Diagn Lab Immunol; 2003 Mar; 10(2):293-302. PubMed ID: 12626457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of CD8+ lymphocytes in host defense against Pneumocystis carinii in mice.
    Beck JM; Newbury RL; Palmer BE; Warnock ML; Byrd PK; Kaltreider HB
    J Lab Clin Med; 1996 Nov; 128(5):477-87. PubMed ID: 8900290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumocystis carinii organisms obtained from rats, ferrets, and mice are antigenically different.
    Bauer NL; Paulsrud JR; Bartlett MS; Smith JW; Wilde CE
    Infect Immun; 1993 Apr; 61(4):1315-9. PubMed ID: 8454333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo.
    Bartlett MS; Current WL; Goheen MP; Boylan CJ; Lee CH; Shaw MM; Queener SF; Smith JW
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1811-6. PubMed ID: 8843286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A rat model for combined Trypanosoma cruzi and Pneumocystis carinii infection.
    Oz HS; Hughes WT; Varilek GW
    Microb Pathog; 2000 Dec; 29(6):363-5. PubMed ID: 11095921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes.
    Shellito J; Suzara VV; Blumenfeld W; Beck JM; Steger HJ; Ermak TH
    J Clin Invest; 1990 May; 85(5):1686-93. PubMed ID: 2139668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of CD40 ligand and other immunomodulators on Pneumocystis carinii infection in rat model.
    Oz HS; Hughes WT; Rehg JE; Thomas EK
    Microb Pathog; 2000 Sep; 29(3):187-90. PubMed ID: 10968950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunologic comparisons of Pneumocystis carinii strains obtained from rats, ferrets, and mice using convalescent sera from the same sources.
    Bauer NL; Paulsrud JR; Bartlett MS; Smith JW; Wilde CE
    J Protozool; 1991; 38(6):166S-168S. PubMed ID: 1818152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inoculated mouse model of Pneumocystis carinii infection.
    Bartlett MS; Queener SF; Durkin MM; Shaw MA; Smith JW
    Diagn Microbiol Infect Dis; 1992 Feb; 15(2):129-34. PubMed ID: 1572137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [An animal model of Pneumocystis carinii pneumonia and therapeutic efficacy of interferon-gamma in this model].
    Nakamoto A; Kitsukawa K; Ishimine T; Inadome J; Kusano N; Fukuhara H; Saito A
    Kansenshogaku Zasshi; 1993 Oct; 67(10):971-7. PubMed ID: 8254217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.